Atherogenesis and the humoral immune response to modified lipoproteins
about
Cholesterol and benign prostate disease.Oxidized LDL: diversity, patterns of recognition, and pathophysiology.Ligation of macrophage Fcγ receptors recapitulates the gene expression pattern of vulnerable human carotid plaquesModified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease.Signaling and cytotoxic functions of 4-hydroxyalkenals.Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes.Integrative pathway dissection of molecular mechanisms of moxLDL-induced vascular smooth muscle phenotype transformationThe levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT studyMethotrexate in atherogenesis and cholesterol metabolismGene Deficiency in Activating Fcγ Receptors Influences the Macrophage Phenotypic Balance and Reduces Atherosclerosis in Mice.Using oxidized low-density lipoprotein autoantibodies to predict restenosis after balloon angioplasty in patients with acute myocardial infarctionThe vicious circle between oxidative stress and inflammation in atherosclerosis.Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury.Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases.Targeting inflammation in cardiovascular diseases. still a neglected field?Can we vaccinate against atherosclerosis?Multiple potential roles for B cells in atherosclerosis.Testing of serum atherogenicity in cell cultures: questionable data published.Anti-oxidized low-density lipoprotein (oxLDL) antibody levels are not related to increasing circulating oxLDL concentrations during the course of pregnancy.Characteristics of Lipoprotein(a)-Containing Circulating Immune Complexes as Markers of Coronary Heart Disease.
P2860
Q33732687-24395ECD-4D6B-4E40-B0DF-6A12BC61523DQ33879138-74638750-5704-40C9-97C7-8540C5D75D5BQ33981389-D4904F79-2535-47DC-862F-C154504AB6CAQ34072528-C69A7087-45F9-4DEF-BBF4-6C645CA2578FQ34139329-13FF9B26-A295-4B9D-BA73-634529F74135Q34527165-9F847B2B-9753-468F-BFB8-0F7773B9B567Q34549788-DF8DD236-7C19-4CAA-A0EE-0D5EACB4AD87Q34557344-8C63DE6C-F462-4EB2-A44F-8A27DDF48C4EQ34757801-596D8E0B-024F-481A-869F-04C94AC7C623Q34785574-09D83A90-4A3B-4ACC-A7FC-D3DAEBBAF29CQ35008989-E1948E20-BB66-49F4-8ACA-AE3695750F85Q37334949-D92CF4EB-2C66-4CD3-9B04-7952664FCBB4Q37436638-55B7BDD3-2476-476F-BB46-8DCCFDED7479Q37824302-E3B37D5C-BBC9-4C05-A604-E4CCFB15728AQ37925018-E43D155F-0745-44F4-9C63-632E97D63248Q38137846-1A6FB0FA-4F5D-4F3D-99D8-ED8CB8814F2AQ38210609-8D1468AA-1FAA-42DE-B452-8AD978AF4330Q43080409-583156A8-413F-49C8-91B4-0E839B45D177Q49168568-D4D5D0EA-95B7-43BD-8FC6-CEE675B3D42BQ51293599-1A3B9747-3163-44B4-92F0-0AC7AE0D9C0E
P2860
Atherogenesis and the humoral immune response to modified lipoproteins
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Atherogenesis and the humoral immune response to modified lipoproteins
@en
Atherogenesis and the humoral immune response to modified lipoproteins.
@nl
type
label
Atherogenesis and the humoral immune response to modified lipoproteins
@en
Atherogenesis and the humoral immune response to modified lipoproteins.
@nl
prefLabel
Atherogenesis and the humoral immune response to modified lipoproteins
@en
Atherogenesis and the humoral immune response to modified lipoproteins.
@nl
P2860
P1433
P1476
Atherogenesis and the humoral immune response to modified lipoproteins
@en
P2093
Gabriel Virella
Maria F Lopes-Virella
P2860
P304
P356
10.1016/J.ATHEROSCLEROSIS.2008.03.025
P577
2008-04-12T00:00:00Z